User login
Pioglitazone, which is used to treat type 2 diabetes, may reduce the risk of recurrent stroke and heart attacks by 24% in people who are insulin resistant but do not have diabetes, according to findings from the Insulin Resistance Intervention after Stroke (IRIS) trial. The study, supported by the National Institute of Neurological Disorders and Stroke, is the first to provide evidence that suggests a drug that targets cell metabolism may be protective against recurrent vascular events even before diabetes develops. More information on the study is available at Federal Practitioner: http://www.fedprac.com/the-publication/issue-single-view/diabetes-drug-reduces-recurrent-vascular-events/bd40f959f882ada3b88cfaa670c4fa44/ocregister.html.
Pioglitazone, which is used to treat type 2 diabetes, may reduce the risk of recurrent stroke and heart attacks by 24% in people who are insulin resistant but do not have diabetes, according to findings from the Insulin Resistance Intervention after Stroke (IRIS) trial. The study, supported by the National Institute of Neurological Disorders and Stroke, is the first to provide evidence that suggests a drug that targets cell metabolism may be protective against recurrent vascular events even before diabetes develops. More information on the study is available at Federal Practitioner: http://www.fedprac.com/the-publication/issue-single-view/diabetes-drug-reduces-recurrent-vascular-events/bd40f959f882ada3b88cfaa670c4fa44/ocregister.html.
Pioglitazone, which is used to treat type 2 diabetes, may reduce the risk of recurrent stroke and heart attacks by 24% in people who are insulin resistant but do not have diabetes, according to findings from the Insulin Resistance Intervention after Stroke (IRIS) trial. The study, supported by the National Institute of Neurological Disorders and Stroke, is the first to provide evidence that suggests a drug that targets cell metabolism may be protective against recurrent vascular events even before diabetes develops. More information on the study is available at Federal Practitioner: http://www.fedprac.com/the-publication/issue-single-view/diabetes-drug-reduces-recurrent-vascular-events/bd40f959f882ada3b88cfaa670c4fa44/ocregister.html.